2023-508369-34-00Active, not recruitingPhase 1
Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Aug 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 89 (estimated)
- First submitted
- 20 Dec 2023
- Start date
- 7 Dec 2021
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Mesothelioma
- EU CT number
- 2023-508369-34-00
- EudraCT number
- 2021-000383-30
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 89
- 6 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Essen (AoR) | Essen | Germany | Active, not recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Active, not recruiting |
| Institut Gustave Roussy | Villejuif | France | Active, not recruiting |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Active, not recruiting |
| Humanitas Research Hospital | Rozzano | Italy | Active, not recruiting |
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Netherlands | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.